Loading clinical trials...
Loading clinical trials...
Prospective, Single-Center, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy With Pegylated Interferon, Ribavirin, and Boceprevir in Patients With Genotype 1 Chronic HCV With End Stage Renal Disease
Conditions
Interventions
P-IFN alfa 2a
P-IFN alfa 2b
+2 more
Start Date
May 1, 2013
Primary Completion Date
February 1, 2015
Completion Date
February 1, 2015
Last Updated
September 23, 2015
NCT07146854
NCT04163614
NCT04580420
NCT06190717
NCT05654103
NCT03994471
Lead Sponsor
Columbia University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions